151 related articles for article (PubMed ID: 33399689)
1. [Refractory myasthenia gravis with good response to rituximab. Report of one case].
Suárez H F; Urrutia E D
Rev Med Chil; 2020 Jul; 148(7):1031-1033. PubMed ID: 33399689
[No Abstract] [Full Text] [Related]
2. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
3. Rituximab in refractory myasthenia gravis: Extended prospective study results.
Beecher G; Anderson D; Siddiqi ZA
Muscle Nerve; 2018 Sep; 58(3):452-455. PubMed ID: 29742795
[TBL] [Abstract][Full Text] [Related]
4. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Sudulagunta SR; Sepehrar M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Sathyanarayana D; Gummadi S; Burra HK
Ger Med Sci; 2016; 14():Doc12. PubMed ID: 27790079
[No Abstract] [Full Text] [Related]
5. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
[No Abstract] [Full Text] [Related]
6. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
8. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
[TBL] [Abstract][Full Text] [Related]
9. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
10. Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.
Sachdeva J; Mahesh KV; Shree R; Jain G; Kapila AT; Shashikala TP; Goyal MK; Modi M; Lal V
Indian J Pharmacol; 2020; 52(1):49-52. PubMed ID: 32201447
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
Jonsson DI; Pirskanen R; Piehl F
Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in late-onset myasthenia gravis is safe and effective.
Sahai SK; Maghzi AH; Lewis RA
Muscle Nerve; 2020 Sep; 62(3):377-380. PubMed ID: 32239711
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
15. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
Singh N; Goyal V
J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
[TBL] [Abstract][Full Text] [Related]
16. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
[TBL] [Abstract][Full Text] [Related]
17. Prospective studies on the efficacy of rituximab for myasthenia gravis are warranted.
Finsterer J; Scorza FA; Scorza CA
Eur J Neurol; 2020 Dec; 27(12):e95. PubMed ID: 32749769
[No Abstract] [Full Text] [Related]
18. Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.
Wang J; Wu X; Deng H; Liu Y; Liu H; Fan X; Liu K; Wu J; Zhang HL
Neurosciences (Riyadh); 2016 Jan; 21(1):77-8. PubMed ID: 26818174
[No Abstract] [Full Text] [Related]
19. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C
J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347
[TBL] [Abstract][Full Text] [Related]
20. Rituximab Treatment in
Koul R; Al-Futaisi A; Abdelrahim R; Mani R; Abdwani R; Al-Asmi A
Sultan Qaboos Univ Med J; 2018 May; 18(2):e223-e227. PubMed ID: 30210856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
